Cambridge, UK, 04 February 2021 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces the appointment of Ronald Carter, MD, as Chief Medical Officer (CMO), and the appointment of Tim Sharpington as Chief Operating Officer (COO).
Ron Carter joins the Company as CMO at an important stage of its development, with major development programmes currently underway in Immuno-oncology and IBD. He will be responsible for progressing the clinical development of the Company’s Live Bacterial Therapeutics and Biomarkers, and expanding its clinical footprint beyond the UK.
He has over 30 years of clinical development experience across Europe, the US, Latin America and Asia in biotech and pharmaceutical companies. He joins Microbiotica from prior roles as Chief Medical Officer at Mologen, Indivumed, and MaaTPharma, where he progressed full ecosystem microbiome restoration therapy for cancer patients. Most recently, he held the role of Senior Medical Director at Seres Therapeutics. He has previous experience within the microbiome space, having taken charge of multiple first-in-man studies across Europe that involved faecal microbiota transplantation in leukemia and GvHD (graft-versus-host disease).
Tim Sharpington has held executive and Board-level leadership positions in pharma, biotech and CRO companies in the UK and US. Tim has established a track record of leading, developing and executing company strategy, with experience in product development, fundraising, M&A and licensing. Prior companies in include hVIVO, Vectura, Ixixo, Arakis Ltd, ICON, Sequus Pharmaceuticals and Pfizer. Tim has led the successful development of several pharmaceutical products in the anti-infective, oncology and anti-inflammatory areas.
As COO, Tim will be responsible for development strategy and development operations across the Company, working closely with CEO Mike Romanos to develop and execute the Company’s corporate strategy and financing. He will also work closely with the Company’s CMO and Chief Scientific Officer, managing Microbiotica’s product portfolio.
Mike Romanos, CEO of Microbiotica, said: “We’re delighted to welcome Ron and Tim to the Company. These appointments strengthen the Company’s management team further. Tim has strong experience in biotech leadership roles and in the strategy and operations of product development in the biotech space, and will be of great value to the Company as we advance our portfolio and partnerships. Ron has a wealth of expertise in clinical development of both oncology and microbiome therapeutics whose knowledge in executing clinical programmes will be instrumental in helping us progress development of our best-in-class Live Bacterial Therapeutic products. I look forward to working closely with both of them.”
Ron Carter, CMO of Microbiotica, said: “Having previously worked in the microbiome space, I firmly believe in the potential that this field has to impact all aspects of medicine. Microbiotica’s discovery platform enables the precise identification of specific bacterial signatures that drive patient phenotype and can serve as therapeutics or biomarkers. I am excited by the opportunity to oversee the Company’s clinical development and help bring successful Live Bacterial Therapeutics and Biomarkers to areas of unmet medical need.”
Tim Sharpington, COO of Microbiotica, said: “Microbiotica is at the forefront of the microbiome field, and is at an important and exciting stage of its development. I’m looking forward to getting started and working with the rest of the management team to help develop and execute the best corporate strategy to build further value for the Company’s shareholders.”
Microbiotica is a leading player in the field of microbiome-based therapeutics, biomarkers and targets. The Company is building a growing pipeline of best-in-class differentiated products based on high quality clinical datasets and unique bacterial signatures that drive biology, identified by its proprietary platform.
Consisting of the world’s leading microbiome Reference Genome Database, Culture Collection, mass culturing technology (Personalised Bacterial Bank) and proprietary AI tools, Microbiotica’s platform enables unrivalled strain-level microbiome analysis linked to patient phenotypes. The Company’s current therapeutic areas of focus are immuno-oncology and IBD, and it has established major clinical and academic partnerships, including a $534m collaboration with Genentech.
Spun out of the Sanger Institute in 2016 by Dr Mike Romanos, Dr Trevor Lawley and Professor Gordon Dougan, the Company is based at Chesterford Research Park near Cambridge, UK. Microbiotica’s investor syndicate includes Cambridge Innovation Capital, IP Group plc and Seventure Partners.
For more information please contact: email@example.com
Melanie Toyne-SewellManaging Partner